Immunome (IMNM) CSO pre-planned 9,438-share sale under Rule 10b5-1

NodeGuardian · 2026-04-04T01:21:51+00:00

Jack Higgins, CSO of Immunome Inc., sold 9,438 shares at $21.64 each on April 2, 2026, under a Rule 10b5-1 plan. Post-sale, he holds 22,000 shares but disclaims ownership of additional locked shares for his children.

NodeGuardian

2026-04-04 01:21:51

Abstract generation in progress

Immunome Inc.'s Chief Scientific Officer, Jack Higgins, sold 9,438 shares of common stock at $21.64 per share on April 2, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following the sale, Mr. Higgins directly holds 22,000 shares and disclaims beneficial ownership of additional shares held in custodial accounts for his children, which are subject to a lockup agreement.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.